Neurotech International (ASX:NTI) - Cours de l'action, nouvelles et analyse

La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

NTI Aperçu des actions

Neurotech International Limited, avec ses filiales, se consacre à la recherche, à la conception, au développement et à la fabrication de dispositifs et de solutions médicales en Australie.

A propos de l'entreprise

NTI analyse fondamentale
Score flocon de neige
Évaluation	0/6
Croissance future	2/6
Performances passées	0/6
Santé financière	6/6
Dividendes	0/6

Récompenses

Les revenus devraient augmenter 39.94% par an

Analyse des risques

Actuellement non rentable et ne devrait pas le devenir au cours des 3 prochaines années

Shareholders have been diluted in the past year

Does not have meaningful revenue (A$3M)

Does not have a meaningful market cap (A$79M)

Neurotech International Limited Concurrents

Micro-X

ASX:MX1

AU$38.4m

EMVision Medical Devices

ASX:EMV

AU$184.5m

SomnoMed

ASX:SOM

AU$84.3m

Austco Healthcare

ASX:AHC

AU$79.4m

Historique des prix et performances

Résumé des plus hauts, des changements et des baisses de prix pour Neurotech International
Historique des cours de bourse
Prix actuel de l'action	AU$0.072
Plus haut sur 52 semaines	AU$0.13
Plus bas sur 52 semaines	AU$0.043
Bêta	1.53
1Variation sur 1 mois	-7.69%
Variation sur 3 mois	-4.00%
Variation sur 1 an	53.19%
3Variation sur 3 ans	53.19%
Variation sur 5 ans	414.29%
Évolution depuis l'introduction en bourse	-74.74%

Nouvelles et mises à jour récentes

Here's Why We're Watching Neurotech International's (ASX:NTI) Cash Burn Situation

Jan 28

Recent updates

Here's Why We're Watching Neurotech International's (ASX:NTI) Cash Burn Situation

Jan 28

We Think Neurotech International (ASX:NTI) Needs To Drive Business Growth Carefully

Oct 14

Here's Why We're Not Too Worried About Neurotech International's (ASX:NTI) Cash Burn Situation

Jul 01

Is Neurotech International (ASX:NTI) In A Good Position To Invest In Growth?

Jan 21

Is Neurotech International (ASX:NTI) In A Good Position To Deliver On Growth Plans?

Oct 06

Here's Why We're Watching Neurotech International's (ASX:NTI) Cash Burn Situation

May 18

We're Not Very Worried About Neurotech International's (ASX:NTI) Cash Burn Rate

Dec 21

Neurotech International (ASX:NTI) Is In A Good Position To Deliver On Growth Plans

Sep 04

Need To Know: Neurotech International Limited (ASX:NTI) Insiders Have Been Selling Shares

Dec 08

Rendement pour les actionnaires

	NTI	AU Medical Equipment	AU Marché
7D	9.1%	-6.2%	2.2%
1Y	53.2%	11.3%	11.2%

Rendement vs Industrie: NTI exceeded the Australian Medical Equipment industry which returned 11.3% over the past year.

Rendement vs marché: NTI exceeded the Australian Market which returned 11.2% over the past year.

Volatilité des prix

Is NTI's price volatile compared to industry and market?
NTI volatility
NTI Average Weekly Movement	10.3%
Medical Equipment Industry Average Movement	10.1%
Market Average Movement	8.2%
10% most volatile stocks in AU Market	16.9%
10% least volatile stocks in AU Market	3.4%

Cours de l'action stable: NTI n'a pas connu de volatilité de prix significative au cours des 3 derniers mois.

Volatilité au fil du temps: NTI's weekly volatility (10%) has been stable over the past year.

À propos de l'entreprise

Fondée	Salariés	PDG	Site web
2016	n/a	Peter James Griffiths	www.neurotechinternational.com

Neurotech International Limited, avec ses filiales, se consacre à la recherche, à la conception, au développement et à la fabrication de dispositifs et de solutions médicales en Australie. La société se concentre sur le développement et la commercialisation de la plateforme Mente, une plateforme technologique pour surveiller et jouer un rôle dans les thérapies à domicile. Ses produits comprennent Mente Autism pour le diagnostic et le traitement de l'autisme.

Neurotech International Limited Résumé des fondamentaux

Comment les bénéfices et les revenus de Neurotech International se comparent-ils à sa capitalisation boursière ?
NTI statistiques fondamentales
Capitalisation boursière	AU$79.36m
Bénéfices(TTM)	-AU$4.98m
Recettes(TTM)	AU$3.20m

22.9x

Ratio P/S

-14.7x

Ratio P/E

Le site NTI est-il surévalué ?

Voir Juste valeur et analyse de l'évaluation

Bénéfices et recettes

Principales statistiques de rentabilité tirées du dernier rapport sur les bénéfices (TTM)
NTI compte de résultat (TTM)
Recettes	AU$3.20m
Coût des recettes	AU$28.87k
Marge brute	AU$3.18m
Autres dépenses	AU$8.16m
Les revenus	-AU$4.98m

Derniers bénéfices déclarés

Dec 31, 2023

Prochaine date de publication des résultats

s/o

Résultat par action (EPS)	-0.0049
Marge brute	99.10%
Marge bénéficiaire nette	-155.47%
Ratio dettes/capitaux propres	0%

Quelles ont été les performances à long terme de NTI?

Voir les performances historiques et les comparaisons

NTI Aperçu des actions

Récompenses

Analyse des risques

Neurotech International Limited Concurrents

ASX:MX1

AU$38.4m

ASX:EMV

AU$184.5m

ASX:SOM

AU$84.3m

ASX:AHC

AU$79.4m

Historique des prix et performances

Nouvelles et mises à jour récentes

Less than half of directors are independent

Neurotech International Limited has completed a Follow-on Equity Offering in the amount of AUD 10 million.

Neurotech International Limited has completed a Follow-on Equity Offering in the amount of AUD 10 million.

Here's Why We're Watching Neurotech International's (ASX:NTI) Cash Burn Situation

Independent Non-Executive Director exercised options to buy AU$114k worth of stock.

Neurotech International Limited to Report Q1, 2024 Results on Oct 27, 2023

Recent updates

Less than half of directors are independent

Neurotech International Limited has completed a Follow-on Equity Offering in the amount of AUD 10 million.

Neurotech International Limited has completed a Follow-on Equity Offering in the amount of AUD 10 million.

Here's Why We're Watching Neurotech International's (ASX:NTI) Cash Burn Situation

Independent Non-Executive Director exercised options to buy AU$114k worth of stock.

Neurotech International Limited to Report Q1, 2024 Results on Oct 27, 2023

Neurotech International Limited, Annual General Meeting, Nov 15, 2023

We Think Neurotech International (ASX:NTI) Needs To Drive Business Growth Carefully

Full year 2023 earnings released: AU$0.01 loss per share (vs AU$0.005 loss in FY 2022)

New minor risk - Financial data availability

Neurotech International Limited to Report Q4, 2023 Results on Jul 26, 2023

New minor risk - Share price stability

Here's Why We're Not Too Worried About Neurotech International's (ASX:NTI) Cash Burn Situation

First half 2023 earnings released: AU$0.48 loss per share (vs AU$0.003 loss in 1H 2022)

Neurotech International Limited Announces First Patient Treated in Phase I/II PANDAS/PANS Trial

Neurotech International Limited Announces Approval for Additional Phase I/II ASD Trial Extension

Neurotech International Limited Receives HREC Approval for Phase I/II PANDAS/PANS Clinical Trial

Neurotech International Limited to Report Q3, 2023 Results on Jan 30, 2023

Is Neurotech International (ASX:NTI) In A Good Position To Invest In Growth?

Neurotech International Limited Announces Grant of FDA Pre-IND Meeting for NTI164 in ASD

Neurotech International Limited Announces Passing of Professor Allan Cripps AO, Non-Executive Director

Neurotech International Limited Announces Commencement of Patient Randomisation and First Patient Successfully Treats Under New Phase II/III NTIASD2 Clinical Trial for Children with Autism Spectrum Disorder

Less than half of directors are independent

Neurotech International Limited, Annual General Meeting, Nov 30, 2022

Neurotech International Limited, Annual General Meeting, Nov 23, 2022

Neurotech International Limited Reports Further Significant Clinical Improvement at 20 Weeks for Paediatric Autism Patients Treated with NTI164

Neurotech International Limited Announces New Phase I/II Clinical Trial in Children with PANDAS/PANS

Is Neurotech International (ASX:NTI) In A Good Position To Deliver On Growth Plans?

Neurotech International Limited Provides Autism Spectrum Disorder Phase I/II Clinical Trial Update

Less than half of directors are independent

Neurotech International Limited Announces Transition of Alexandra Andrews from Chief Executive Officer to a New Position of Chief Operating Officer

Full year 2022 earnings released: AU$0.005 loss per share (vs AU$0.015 loss in FY 2021)

Neurotech International Limited Announces Currently Finalising a Pivotal Phase II/III Clinical Trial Design to be Conducted in Australia

Neurotech International ORDINARY FULLY PAID to Be Deleted from OTC Equity

Neurotech International Limited Announces Executive Changes

Neurotech International Limited Announces Results with NTI164 in Paediatric ASD

High number of new directors

Here's Why We're Watching Neurotech International's (ASX:NTI) Cash Burn Situation

Neurotech International Limited Announces Important Developments Relating to the Study Protocol Assessing NTI164 in Children with Autism Spectrum Disorder

High number of new directors

Neurotech International Limited Announces Successful Developments Relating to Safety and Tolerability of NTI164 and Key Behavioural Parameters That Impact Autism Spectrum Disorder Patients

Neurotech International Limited Appoints Alexandra Andrews as Chief Executive Officer, Effective 8 March 2022

We're Not Very Worried About Neurotech International's (ASX:NTI) Cash Burn Rate

Neurotech International Limited Announces Nti164 Clinical Program Update

Neurotech International (ASX:NTI) Is In A Good Position To Deliver On Growth Plans

Full year 2021 earnings released: AU$0.015 loss per share (vs AU$0.011 loss in FY 2020)

Neurotech International Limited Announces the Continuation of Its Pre-Clinical Program in Neuro-Inflammatory Disease Models In-Line with Research and Development Pathway

Neurotech International Limited Initiates Phase I/II Open Label Study into Autism

Neurotech International Limited has completed a Follow-on Equity Offering in the amount of AUD 2 million.

Neurotech International Limited Announces Strategic Cultivation Partnership with CannaPacific Limited

Neurotech International Limited Announces the Expansion of Its Exclusive License with Dolce Cann Global Pty Ltd

Neurotech International Limited Provides an Update on Clinical Study Program

Neurotech International Limited has completed a Follow-on Equity Offering in the amount of AUD 2.5 million.

Need To Know: Neurotech International Limited (ASX:NTI) Insiders Have Been Selling Shares

Neurotech International Limited Announces Initiation of Clinical Product Formulation Studies

Neurotech International Limited Announces Transition of Peter Griffiths as CEO

Neurotech International Limited Commences Landmark in Vitro Trials of Unique Cannabis Strains

Full year earnings released - AU$0.011 loss per share

Rendement pour les actionnaires